Clinical Trials

370 enrolled 2 FDA

Advanced Non-small Cell Lung Cancer

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 1 FDA

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT02609776 2026-04-13

CHRYSALIS

751 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02864992 2026-04-13

VISION

337 enrolled 13 charts 4 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03145181 2026-04-13

MajesTEC-1

Other hematologic neoplasm

302 enrolled 2 FDA

Hematologic Neoplasms

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 2 FDA

Plasma cell

Smoldering Multiple Myeloma

NCT03399799 2026-04-13

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 2 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 2 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04557098 2026-04-13

MajesTEC-1

Other hematologic neoplasm

194 enrolled 2 FDA

Hematologic Neoplasms

NCT04634552 2026-04-13

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 2 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04640623 2026-04-13

SunRISe-1

220 enrolled 2 FDA

Urinary Bladder Neoplasms

NCT04924075 2026-04-13

MK-6482-015

Phase 2 Recruiting

322 enrolled 2 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Plasma cell

Multiple Myeloma

NCT04099251 2026-04-09

CheckMate76K

790 enrolled 18 charts 2 FDA

Dermatologic

Melanoma

NCT04482309 2026-04-09

DPT02

477 enrolled 2 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03625037 2026-04-08

EPCORE™ NHL-1

LymphoidOther hematologic neoplasm

666 enrolled 4 FDA

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT03962543 2026-04-08

ReNeu

114 enrolled 25 charts 2 FDA

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT04404660 2026-04-08

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

153 enrolled 2 FDA

Lymphoid

Burkitt Lymphoma, Recurrence

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 2 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03075696 2026-04-03

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Phase 1/2 Recruiting

940 enrolled 2 FDA

Lymphoid

Lymphoma, Non-Hodgkin

NCT03093116 2026-04-03

TRIDENT-1

Phase 1/2 Recruiting

500 enrolled 4 FDA

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04589845 2026-04-02

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

920 enrolled 2 FDA

Other solid neoplasm

Solid Tumors

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 3 FDA

Breast

Breast Neoplasms

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

415 enrolled 2 FDA

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT02650401 2026-03-25

STARTRK-NG

CNSEndocrineGenitourinaryHead & NeckSarcoma

69 enrolled 2 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

98 enrolled 18 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

1,069 enrolled 19 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04484142 2026-03-24

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Phase 2 Completed

137 enrolled 9 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

605 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 2 FDA